CGEN official logo CGEN
CGEN 2-star rating from Upturn Advisory
Compugen (CGEN) company logo

Compugen (CGEN)

Compugen (CGEN) 2-star rating from Upturn Advisory
$1.63
Last Close (24-hour delay)
upturn advisory logo
PASS
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock price based on last close icon Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • 1Y
  • 1M
  • 1W

Upturn Advisory Summary

12/10/2025: CGEN (2-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

Upturn 2 star rating for performance

Below Average Performance

These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.

Number of Analysts

1 star rating from financial analysts

4 Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $6.25

1 Year Target Price $6.25

Analysts Price Target For last 52 week
$6.25 Target price
52w Low $1.13
Current$1.63
52w High $2.66

Analysis of Past Performance

Type Stock
Historic Profit 214.4%
Avg. Invested days 39
Today’s Advisory PASS
Upturn Star Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 3.0
Stock Returns Performance Upturn Returns Performance icon 5.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 12/10/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 155.32M USD
Price to earnings Ratio -
1Y Target Price 6.25
Price to earnings Ratio -
1Y Target Price 6.25
Volume (30-day avg) 4
Beta 2.83
52 Weeks Range 1.13 - 2.66
Updated Date 12/10/2025
52 Weeks Range 1.13 - 2.66
Updated Date 12/10/2025
Dividends yield (FY) -
Basic EPS (TTM) -0.3

Analyzing Revenue: Products, Geography and Growth

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date 2025-11-10
When -
Estimate -0.065
Actual -0.07

Profitability

Profit Margin -
Operating Margin (TTM) -417.4%

Management Effectiveness

Return on Assets (TTM) -18.18%
Return on Equity (TTM) -52.95%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 59030517
Price to Sales(TTM) 22.5
Enterprise Value 59030517
Price to Sales(TTM) 22.5
Enterprise Value to Revenue 8.51
Enterprise Value to EBITDA -19.16
Shares Outstanding 93535357
Shares Floating 91599511
Shares Outstanding 93535357
Shares Floating 91599511
Percent Insiders 2.03
Percent Institutions 13.66

Icon representing Upturn AI-generated SWOT analysis summary Upturn AI SWOT

Compugen

Compugen(CGEN) company logo displayed in Upturn AI summary

Company Overview

Company history and background logo History and Background

Compugen Ltd. was founded in 1990 in Israel and has since evolved into a leading provider of IT solutions and services. The company has a history of adapting to technological shifts, focusing on cloud computing, data analytics, cybersecurity, and digital transformation. It has grown through organic expansion and strategic partnerships, establishing a significant presence in its target markets.

Company business area logo Core Business Areas

  • Cloud Solutions: Design, implementation, and management of cloud infrastructure and services, including public, private, and hybrid cloud environments. This involves migration, optimization, and ongoing support for cloud platforms like AWS, Azure, and Google Cloud.
  • Data and AI: Leveraging data analytics, machine learning, and artificial intelligence to help organizations extract insights, optimize operations, and drive innovation. This includes data warehousing, business intelligence, predictive analytics, and AI-driven solutions.
  • Cybersecurity: Providing comprehensive cybersecurity services and solutions to protect organizations from evolving threats. This encompasses threat detection and response, vulnerability management, identity and access management, and data security.
  • Digital Transformation: Assisting businesses in transforming their operations and customer experiences through the adoption of new technologies and digital strategies. This often involves modernizing applications, optimizing workflows, and enhancing customer engagement.

leadership logo Leadership and Structure

Compugen's leadership team includes individuals with extensive experience in the technology and IT services sector. The organizational structure is designed to support its diverse service offerings and client engagements, often with specialized teams dedicated to specific technology domains or industry verticals.

Top Products and Market Share

Product Key Offerings logo Key Offerings

  • Cloud Migration and Management Services: Compugen offers end-to-end cloud migration services, helping businesses move their applications and data to cloud platforms. Their management services ensure optimal performance, cost-efficiency, and security of cloud environments. Competitors include large cloud providers' professional services arms (AWS Professional Services, Microsoft Consulting Services) and other IT consulting firms like Accenture, IBM, and Capgemini.
  • Big Data Analytics Platforms: Solutions that enable organizations to collect, process, and analyze vast amounts of data to derive actionable insights. These platforms often integrate with various data sources and utilize AI/ML for advanced analytics. Key competitors include Palantir Technologies, Snowflake, and data analytics divisions of tech giants like Google and Microsoft.
  • Advanced Cybersecurity Solutions: A suite of services and technologies designed to protect against sophisticated cyber threats. This includes managed detection and response (MDR), security information and event management (SIEM), and endpoint security. Competitors range from specialized cybersecurity firms like CrowdStrike and Palo Alto Networks to broader IT security providers.

Market Dynamics

industry overview logo Industry Overview

The IT solutions and services market is characterized by rapid technological advancements, particularly in cloud computing, AI, and cybersecurity. There is a strong demand for digital transformation initiatives, with businesses seeking to improve efficiency, customer engagement, and competitive advantage. The market is highly competitive and fragmented, with both large global players and specialized niche providers.

Positioning

Compugen positions itself as a strategic partner for businesses undergoing digital transformation. Its strengths lie in its comprehensive service portfolio, expertise across multiple technology domains, and ability to provide tailored solutions. The company focuses on delivering value through innovation and deep technical knowledge, aiming to be a trusted advisor in a complex technological landscape.

Total Addressable Market (TAM)

The global IT services market is valued in the hundreds of billions of USD and is projected to continue growing steadily. Compugen operates within this expansive market, focusing on specific segments like cloud, data analytics, and cybersecurity. Its positioning is within the mid-to-enterprise level clients seeking specialized IT solutions, representing a significant but not dominant portion of the overall TAM.

Upturn SWOT Analysis

Strengths

  • Broad portfolio of IT solutions and services
  • Strong expertise in cloud, data analytics, and cybersecurity
  • Established client relationships and reputation
  • Agility to adapt to new technologies

Weaknesses

  • Relatively smaller scale compared to global IT giants
  • Dependence on key technology partners
  • Potential challenges in global brand recognition
  • Resource constraints for very large-scale projects

Opportunities

  • Increasing demand for cloud migration and hybrid cloud solutions
  • Growth in AI and machine learning adoption by businesses
  • Rising need for advanced cybersecurity measures
  • Expansion into new geographic markets
  • Strategic partnerships and acquisitions

Threats

  • Intense competition from larger IT service providers
  • Rapid pace of technological change requiring continuous investment
  • Economic downturns impacting IT spending
  • Talent acquisition and retention challenges in the tech sector
  • Data privacy regulations and compliance issues

Competitors and Market Share

Key competitor logo Key Competitors

  • Accenture (ACN)
  • IBM (IBM)
  • Capgemini (CAPP.PA)
  • Tata Consultancy Services (TCS.NS)
  • Infosys (INFY)

Competitive Landscape

Compugen's advantages lie in its specialized expertise and agility. However, it faces significant disadvantages in terms of scale and global brand recognition compared to giants like Accenture and IBM. Its ability to secure and execute large-scale projects might be more limited, but it can excel in offering niche, high-value solutions.

Growth Trajectory and Initiatives

Historical Growth: Compugen has demonstrated a consistent growth trajectory, particularly in its key service areas such as cloud computing and data solutions. Its ability to adapt to market trends and expand its service offerings has fueled this growth over the years.

Future Projections: Future growth is projected to be driven by the continued demand for digital transformation, cloud adoption, and advanced analytics. Analysts often forecast continued revenue expansion, with potential for margin improvement as the company scales its operations and refines its service delivery.

Recent Initiatives: Recent initiatives likely involve strengthening its cybersecurity offerings, expanding its AI/ML capabilities, and forging strategic partnerships with leading technology vendors to enhance its solution portfolio and market reach.

Summary

Compugen is a well-established IT solutions provider with strong expertise in cloud, data, and cybersecurity. Its ability to adapt to market trends and offer tailored digital transformation services is a key strength. However, it faces intense competition from larger players, and its relatively smaller scale presents challenges in capturing market share. Continued investment in innovation and strategic partnerships will be crucial for its sustained growth and success.

Similar Stocks

Sources and Disclaimers

Data Sources:

  • Company investor relations (if publicly traded)
  • Industry analysis reports
  • Financial news outlets
  • Market research firms

Disclaimers:

This analysis is based on publicly available information and general market knowledge. Financial figures and market share data are estimates and may vary. This information should not be considered investment advice. Investors should conduct their own due diligence.

Information icon for Upturn AI Summarization accuracy disclaimer AI Summarization is directionally correct and might not be accurate.

Information icon for Upturn AI Summarization data freshness disclaimer Summarized information shown could be a few years old and not current.

Information icon warning about Upturn AI Fundamental Rating based on potentially old data Fundamental Rating based on AI could be based on old data.

Information icon warning about potential inaccuracies or hallucinations in Upturn AI-generated summaries AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Compugen

Exchange NASDAQ
Headquaters -
IPO Launch date 2000-08-11
CEO & Director Dr. Eran Ophir Ph.D.
Sector Healthcare
Industry Biotechnology
Full time employees 74
Full time employees 74

Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe. The company's pipeline consists of COM701, an immuno-oncology pipeline program with an anti-PVRIG antibody; COM902, a therapeutic anti-TIGIT antibody, are in Phase 1 clinical trials and have been evaluated for the treatment of solid tumors as a monotherapy and in combination of PVRIG/PD-1 and PVRIG/TIGIT, as well as PVRIG/PD-1/TIGIT blockade; Bapotulimab, a therapeutic antibody targeting ILDR2 that is evaluated in Phase I clinical trials in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase III clinical study in patients with advanced or metastatic non-small cell lung cancer. Its preclinical therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and Gilead Sciences, Inc. for the research, development, manufacturing, and commercialization of COM503 and other products. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.